» Articles » PMID: 36268275

LncRNA TRPM2-AS Promotes Colorectal Cancer Progression by Regulating MiR-22-3p and FSTL1

Overview
Journal J Oncol
Specialty Oncology
Date 2022 Oct 21
PMID 36268275
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In recent years, long noncoding RNAs (lncRNAs) relate to many biological processes, which affect the progression of tumors. Transient receptor potential melastatin 2 antisense RNA (TRPM2-AS) is reported to play an oncogene-like role in tumors. TRPM2-AS is highly expressed in colorectal cancer (CRC), but the mechanism of TRPM2-AS is still unclear. The regulatory mechanism of TRPM2-AS in the occurrence of CRC was explored, so as to find new markers and therapeutic targets for CRC.

Methods: TRPM2-AS and miR-22-3p expression in CRC cells were measured through reverse-transcription quantitative polymerase chain reaction (RT-qPCR). Then, TRPM2-AS knockdown cell lines were constructed, and cell counting kit-8 (CCK-8), clone formation, wound healing, and invasion assays were used to detect cell malignant behavior. Follistatin-like 1 (FSTL1) protein was detected by western blotting. The interaction between miR-22-3p and TRPM2-AS or FSTL1 was verified by the luciferase reporter and RNA immunoprecipitation (RIP) assay. Subcutaneous xenografts were performed using animal experiments.

Results: TRPM2-AS expression in CRC cells was increased, and miR-22-3p expression was decreased in CRC cells. TRPM2-AS inhibition inhibited cell malignant behavior. miR-22-3p has a targeting relationship with TRPM2-AS and FSTL1. In cells, downregulation of TRPM2-AS expression promoted miR-22-3p and inhibited FSTL1 expression, while mimics inhibited FSTL1 expression. miR-22-3p inhibition or FSTL1 overexpression could offset the inhibition of TRPM2-AS downregulation on CRC cells.

Conclusions: The TRPM2-AS/miR-22-3p/FSTL1 regulation axis could regulate CRC cell malignant behavior, which may provide a new perspective for interpreting the mechanism of CRC development.

Citing Articles

Clinical Significance and Pathogenic Mechanisms of Long Non-Coding RNA TRPM2-AS in Cancers.

Huang S, Li B, Chen H, Rong C, Yang Z, Zhang X Technol Cancer Res Treat. 2025; 24:15330338251315625.

PMID: 39865876 PMC: 11770775. DOI: 10.1177/15330338251315625.


TRPM2-AS promotes ovarian cancer cell proliferation and inhibits cell apoptosis by upregulating the nearby gene TRPM2 via miR-6764-5p.

Zhu W, Mao S, Jiang J Cell Div. 2024; 19(1):26.

PMID: 39192251 PMC: 11351637. DOI: 10.1186/s13008-024-00130-0.

References
1.
Wang W, Dai Y, Yang X, Xiong X . Long non-coding RNA TRPM2 antisense RNA as a potential therapeutic target promotes tumorigenesis and metastasis in esophageal cancer. Bioengineered. 2022; 13(2):4397-4410. PMC: 9208624. DOI: 10.1080/21655979.2022.2033412. View

2.
Wu Y, Cong L, Chen W, Wang X, Qiu F . lncRNA LINC00963 downregulation regulates colorectal cancer tumorigenesis and progression via the miR‑10b/FGF13 axis. Mol Med Rep. 2021; 23(3). PMC: 7830939. DOI: 10.3892/mmr.2021.11850. View

3.
Lv H, Zhou D, Liu G . LncRNA LINC00963 promotes colorectal cancer cell proliferation and metastasis by regulating miR‑1281 and TRIM65. Mol Med Rep. 2021; 24(5). PMC: 8436205. DOI: 10.3892/mmr.2021.12421. View

4.
Ladabaum U, Dominitz J, Kahi C, Schoen R . Strategies for Colorectal Cancer Screening. Gastroenterology. 2019; 158(2):418-432. DOI: 10.1053/j.gastro.2019.06.043. View

5.
Yang W, Wu Y, Wang C, Liu Z, Xu M, Zheng X . FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3β - dependent manner in hepatocellular carcinoma. Cancer Biomark. 2017; 20(1):75-85. DOI: 10.3233/CBM-170132. View